Management of painful diabetic neuropathy: A treatment algorithm

Journal of the American Podiatric Medical Association

Volumn 87, Issue 8, 1997, Pages 370-379

  Page, Jeffrey C ^a,b,c,d   Chen, Eric Y ^c,d  

^a AMERICAN BOARD OF PODIATRIC SURGERY   (United States)

^b American College of Foot and Ankle Surgeons   (United States)

^c Department of Podiatric Medicine ^*  (United States)

^d California College of Pediatric Medicine San Francisco Campus   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; DIABETIC NEUROPATHY; HUMAN; REVIEW;

ALGORITHMS; DIABETIC NEUROPATHIES; HUMANS;

EID: 0031202925     PISSN: 87507315     EISSN: None     Source Type: Journal    
DOI: 10.7547/87507315-87-8-370     Document Type: Article

References (123)

1. WATKINS PJ: Natural history of the diabetic neuropathies. Q J Med 77: 1209, 1990.
2. THOMAS PK, ELLASSON SG: "Diabetic Neuropathy," in Peripheral Neuropathy, ed by PJ Dyck, PK Thomas, EH Lambert, et al, 2nd Ed, WB Saunders, Philadelphia, 1984.
3. THOMAS PK: "Animal Models of Metabolic Neuropathies," in Peripheral Neuropathy, ed by PJ Dyck, PK Thomas, EH Lambert, et al, 2nd Ed, WB Saunders, Philadelphia, 1984.
4. JUNG SJ, PFEIFER MA: Persons with diabetes and neuropathic symptoms have poor psychosocial adjustments. Diabetes 35 (suppl): 123, 1986.
5. BROWNLEE M, VLASSARA H, CERAMI A: Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101: 537, 1984.
6. GREENE DA, SIMA AFF, ALBERS JW, ET AL: "Diabetic Neuropathy," in Diabetes Mellitus Theory and Practice, 4th Ed, ed by H Rifkin, D Porte, Elsevier, New York, 1990.
7. SAID G, GOULON-GOEAU C, LACROIX C, ET AL: Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 35: 559, 1994.
8. CLEMENTS RS, BELL DS: Diabetic neuropathy: peripheral and autonomie syndromes. Postgrad Med 71: 50, 1982.
9. PARTANEN J, NISKANEN L, LEHTINEN J, ET AL: Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med 333: 89, 1995.
10. PIRART J: Diabète et complications dégénératives: présentation d'une étude prospective portant sur 4,400 cas observés entre 1947 et 1973. première partie. Diabete Metab 3: 97, 1977.
11. LEHTINEN JM, UUSITUPA M, SHTONEN O, ET AL: Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects. Diabetes 38: 1307, 1989.
12. BOULTON AM, KNIGHT G, DRURY J, ET AL: The prevalence of symptomatic diabetic neuropathy in an insulin treated population. Diabetes Care 8: 125, 1985.
13. VEVES A, MANES C, MURRAY HJ, ET AL: Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care 16: 1187, 1993.
14. TOOKE JE: Perspectives in diabetes: microvascular function in human diabetes, a physiological perspective. Diabetes 44: 721, 1995.
15. JULU PO: Essential fatty acids prevent slowed nerve conduction in streptozotocin diabetes. J Diabet Complications 2: 185, 1988.
16. OMAWARI N, DEWHUST M, Vo P: Deficient nitric oxide responsible for reduced nerve blood flow in diabetic rats: effects of L-NAME, L-argenine, sodium nitroprusside and evening primrose oil. Br J Pharmacol 118: 186, 1996.
17. ISHII D: Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev 20: 47, 1995.
18. ARCHER AG, WATKINS PJ, THOMAS PK, ET AL: The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psych 46: 491, 1983.
19. GREENE DA, LATTIMER SA, ULBRECHT J, ET AL: Glucose induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 8: 290, 1985.
20. JULSRUD ME: Diabetic neuropathy. JAPA 71: 318, 1981.
21. JOHNSON PC, DOLL SC, CROMEY DW: Pathogenesis of diabetic neuropathy. Ann Neurol 19: 450, 1986.
22. SIMA AFF: Can the BB-rat help to unravel diabetic neuropathy? Neuropathol Appl Neurobiol 11: 253, 1985.
23. MELTON LJ, DYCK PJ: "Epidemiology," in Diabetic Neuropathy, ed by PJ Dyck, PK Thomas, AK Asbury, et al, WB Saunders, Philadelphia, 1987.
24. DELLON AL, DELLON ES, SEILER WA IV: Effect of tarsal tunnel decompression in the streptozotocin-induced diabetic rat. Microsurgery 15: 265, 1994.
25. DELLON ES, DELLON AL: Functional assessment of neurologic impairment: track analysis in diabetic and compression neuropathies. Plast Reconstr Surg 88: 686, 1990.
26. CAMERON NE, COTTER M, LOW P: Nerve blood flow in early experimental diabetes in rats: relation to conduction deficits. Am J Physiol 261: E1, 1991b.
27. NEWRICK PG, WILSON AJ, JAKUBOWSKI JA, ET AL: Sural nerve oxygen tension in diabetes. Br J Med 293: 1053, 1986.
28. TUCK RR, SCHMELZER JD, LOW PA: Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107: 935, 1984.
29. TESFAYE S, HARRIS N, JAKUBOWSKI J, ET AL: Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: a novel technique of nerve photography and fluorescein angiography. Diabetologia 36: 1266, 1993.
30. BOULTON AJM, SCARPELLO JHB, WARD JD: Venous oxygenation in the diabetic neuropathic foot: evidence of arterio-venous shunting. Diabetologia 22: 6, 1982.
31. BAYS HE, PFEIFER MA: Peripheral diabetic neuropathy. Med Clin North Am 72: 1439, 1988.
32. BENBOW SJ, PRYCE DW, NOBLETT K, ET AL: Flow motion in peripheral diabetic neuropathy. Clin Sci 88: 191, 1995.
33. PIRART J: Diabetic neuropathy: a metabolic or vascular disease? Diabetes 14: 1, 1965.
34. ARCHER AG, ROBERTS VC, WATKINS PJ: Blood flow patterns in painful diabetic neuropathy. Diabetologia 27: 563, 1984.
35. FINEGOLD D: Polyol pathway activity and myo-inositol metabolism. Diabetes 32: 988, 1983.
36. GREENE DA, GREGERSEN G, ZIMMERMAN BR: "Metabolic Control," in Diabetic Neuropathy, ed by PJ Dyck, PK Thomas, AK Asbury, et al, WB Saunders, Philadelphia, 1987.
37. DVORNIK D, PORTE D: Aldose Rcductase Inhibition: An Approach to the Prevention of Diabetic Complications, McGraw-Hill, New York, 1987.
38. JUDZEWWITSCH RG, JASPAN JB, POLONSKY KS, ET AL: Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med 308: 119, 1983.
39. DYCK PJ, ZIMMERMAN BR, VILEN TH, ET AL: Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy. N Engl J Med 319: 544, 1983.
40. PFEIFER MA, Ross DR, SCHRAGE JP, ET AL: A highly successful and novel model for treatment of chronic painful diabetic peripheral neuropathy. Diabetes Care 16: 1103, 1993.
41. YASUDA H, DYCK PJ: Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 37: 20, 1987.
42. GREENE DA, LEWIS RA, LATTIMER SA, ET AL: Selective effects of myo-inositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest 55: 1326, 1975.
43. GREENE DA, LEWIS RA, LATTIMER SA, ET AL: Selective effects of myo-inositol administration on sciatic and tibial motor nerve conduction parameters in the streptozotocin-diabetic rat. Diabetes 31: 573, 1982.
44. MAYER JH, TOMLINSON DR: The influence of aldose reductase inhibition and nerve myo-inositol on axonal transport and nerve conduction velocity in rats with experimental diabetes. J Physiol 340: 25, 1983.
45. SIMA AFF, BRIL V, NATHANIEL V, ET AL: Regeneration and repair of myelinated fibers in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med 317: 548, 1988.
46. CARAVATI CM: Insulin neuritis: a case report. Va Med Mon 59: 745, 1933.
47. ELLENBERG M: Diabetic neuropathy precipitating after institution of diabetic control. Am J Med Sci 236: 466, 1958.
48. KRENTZ AJ: Acute symptomatic diabetic neuropathy associated with normalisation of haemoglobin A1. J Ro Soc Med 82: 767, 1989.
49. LLEWELYN JG, THOMAS PK, FONSECA V, ET AL: Acute painful diabetic neuropathy precipitated by strict glycaemic control. Acta Neuropathol 72: 157, 1986.
50. TESFAYE S, MALIK R, WARD JD: Vascular factors in diabetic neuropathy. Diabetologia 37: 847, 1994.
51. BOULTON AJM, SCARPELLO JHB, ARMSTRONG WD, ET AL: The natural history of painful diabetic neuropathy: a 4-year study. Postgrad Med J 59: 566, 1983.
52. YOUNG RJ, EWING DJ, CLARKE BF: Chronic and remitting painful diabetic polyneuropathy: correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care 11: 34, 1988.
53. WALTERS AS, HICKEY K, MALTZMAN J, ET AL: A questionnaire study of 138 patients with restless legs syndrome: the night-walkers' survey. Neurology 46: 92, 1996.
54. UCCIOLI L, GIACOMINI PG, MONTICONE G, ET AL: Body sway in diabetic neuropathy. Diabetes Care 18: 339, 1995.
55. ASBURY AK, FIELDS HL: Pain due to peripheral nerve damage: an hypothesis. Neurology 34: 1587, 1984.
56. CLEMENTS R, BELL DS: Diagnostic, pathogenetic, and therapeutic aspects of diabetic neuropathy. Spec Top Endocrinol Metab 3: 1, 1982.
57. BOULTON AJM, DRURY J, CLARKE B, ET AL: Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 5: 386, 1982.
58. SANTIAGO JV: Lessons from the diabetes control and complications trial. Diabetes 42: 1549, 1993.
59. RICHELSON E: "Antidepressants: Pharmacology and Clinical Use," in American Psychiatric Association Task Force on Treatments of Psychiatric Disorders: Treatments of psychiatric disorders, Vol 3, American Psychiatric Association, Washington, DC, 1989.
60. MAX MB: Effect of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326: 1250, 1992.
61. ELLENBERG M: Treatment of diabetic neuropathy with diphenylhydantoin. NYJ Med 68: 2653, 1968.
62. SANDEK CD, WERNS S, REIDENBERG MM: Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22: 196, 1977.
63. KANNAN K, DASH RJ, RASTOGI GK: Evaluation of treatment of painful diabetic neuropathy with diphenylhydantoin. J Diabetes Assoc India 18: 199, 1978.
64. RULL JA, QUIBERA R, GONZALES-MILLAN H, ET AL: Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double-blind cross-over trials. Diabetologia 5: 215, 1969.
65. GEE NS, BROWN JP, DISSANAYAKE VU, ET AL: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271: 5768, 1996.
66. KONDO T, FROMM GH, SCHMIDT B: Comparison of gabapentin with other antiepileptic and GABAergic drugs. Epilepsy Res 8: 226, 1991.
67. MELLICK GA, MELLICK LB: Gabapentin in the management of reflex sympathetic dystrophy. J Pain Symptom Manage 10: 265, 1995
68. MELLICK LB, MELLICK GA: Successful treatment of reflex sympathetic dystrophy with gabapentin. Am J Emerg Med 13: 96, 1995.
69. MELLICK GA, SENG ML: The use of gabapentin in the treatment of reflex sympathetic dystrophy and a phobic disorder. Am J Pain Management 5: 7, 1995.
70. SEGAL AZ, RORDORF G: Gabapentin as a novel treatment for postherapetic neuralgia. Neurology 46: 1175, 1996.
71. ROSNER H, RUBIN L, KESTENBAUM A: Gabapentin adjunctive therapy in neuropathic pain states. Clin J Pain 12: 56, 1996.
72. MATHER NT, LUCKER C: Gabapentin in migraine prophylaxis: a perliminary open label study. Neurology 46: A169, 1996.
73. DEJGARD A, PETERSEN P, KASTRUP J: Mexiletine for treatment of chronic painful diabetic neuropathy. Lancet 2: 9, 1988.
74. KASTRUP J, ANGELO HR, PETERSON P, ET AL: Treatment of chronic painful diabetic neuropathy with intravenous lidocaine infusion (abstract). Br Med J 292: 173, 1986.
75. KASTRUP J, PETERSON P, DEJGARD A, ET AL: Intravenous lidocaine infusion: a new treatment of chronic painful diabetic neuropathy? Pain 28: 69, 1987.
76. BACH FW, JENSEN TS, KASTRUP J, ET AL: The effect of intravenous lidocaine on nociceptive processing in diabetic neuropathy. Pain 40: 29, 1990.
77. WARD A, CLISSOLD SP: Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34: 50, 1987.
78. PREGO MA, SERGIO G, ARTALE F, ET AL: Haemorrheological improvement by pentoxifylline in patients with peripheral arterial occlusive disease. Curr Med Res Opin 10: 135, 1986.
79. SCHUBOTZ R: Double-blind trial of pentoxifylline in diabetes with peripheral vascular disorders. Pharmatherapeutica 1: 172, 1976.
80. COHEN KL, HARRIS S: Pentoxifylline and diabetic neuropathy (letter). Ann Intern Med 107: 600, 1987.
81. KALMANSOHN RB, MARKHAM CH, SCHIFF DL: Treatment of diabetic neuropathy with pentoxifylline: case report. Angiology 39: 371, 1988.
82. COHEN KL, LUCIBELLO FE, CHOMIAK M: Lack of effect of clonidine and pentoxifylline in short-term therapy of diabetic peripheral neuropathy. Diabetes Care 13: 1074, 1990.
83. COHEN SM, MATHEWS T: Pentoxifylline in the treatment of distal diabetic neuropathy. Angiology 42: 741, 1991.
84. MERCURI O, PELUFFO RO, BRENNER RR: Depression of microsomal desaturation of linoleic to gamma-linolenic acid in the alloxan diabetic rat. Biochem Biophys Acta 116: 409, 1996.
85. FAAS FH, CARTER WJ: Altered fatty acid desaturation and microsomal fatty acid composition in streptozotocin diabetic rat. Lipids 15: 953, 1980.
86. HARROBIN DF: The roles of essential fatty acids in the development of diabetic neuropathy and other complications of diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 31: 181, 1988.
87. JULU PO: Latency of neuroactivity and optimum period of treatment with evening primrose oil in diabetic rats. J Lipid Mediat Cell Signal 13: 99, 1996.
88. JULU PO, GOW JW, JAMA GA: Endogenous cyclo-oxygenase substrates mediate the neuroactivity of evening primrose oil in rats. J Lipid Mediat Cell Signal 13: 115, 1996.
89. DINES KC, CAMERON NE, COTTER MA: Comparison of the effects of evening primrose oil and triglycerides containing gamma-linolenic acid on nerve conduction and blood flow in diabetic rats. J Pharmacol Exp Ther 273: 49, 1995.
90. JAMAL GA, CARMICHAEL H: The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double blind placebo controlled trial. Diabet Med 7: 319, 1990.
91. KEEN H, PAYAN J, ALLAWI J: Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 16: 8, 1993.
92. CAMERON NE, COTTER MA, ROBERTSON S: Essential fatty acid diet supplementation: effects on peripheral nerve and skeletal muscle function and capillarisation in streptozotocin-induced diabetic rats. Diabetes 40: 532, 1991.
93. JESSELL TM: Pain. Lancet 2: 1084, 1982.
94. LEMDECK F, DONNERER J, CALPAERT FC: Increase of substance P in primary afferent nerves during chronic pain. Neuropeptides 1: 175, 1981.
95. LEMDECK F, GAMSE R, JUAN H: "Substance P and Sensory Nerve Endings," in Substance P, ed by US von Euler, B Pernow, Raven Press, New York, 1977.
96. FITZGERALD M: Capsaicin and sensory neurones: a review. Pain 15: 109, 1983.
97. SCHEFFLER NM, SHEITEL PL, LIPTON MN: Treatment of painful diabetic neuropathy with capsaicin 0.075%. JAPMA 81: 288, 1991.
98. HICKS DR, KRAM LM, CAYEN MN, ET AL: Tolrestat kinetics. Clin Pharmacol Ther 36: 493, 1984.
99. ITOH H, HORIE H, NAMBA M, ET AL: Therapeutic effect of prostaglandin E1 on diabetic neuropathy. J Jpn Diabetes Society 29 (suppl): 88, 1986.
100. HOSHI K, MIZASHIMA Y, KIYOKAWA S, ET AL: Prostaglandin El, incorporated in lipid micropheres in the treatment of peripheral vascular diseases and diabetic neuropathy. Drugs Exp Clin Res 12: 681, 1986.
101. TESFAYE S, WATT J, BENBOW SJ, ET AL: Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet 348: 1698, 1996.
102. TERRENCE CF, FROMM GH, TENICELA R: Baclofen as an analgesic in chronic peripheral nerve disease. Eur Neurol 24: 380, 1985.
103. THOMPSON RHS: "Biochemical Aspects of Diabetic Neuropathy," in Biochemical Aspects of Neurological Disorders, 2nd Series, ed by JN Cummings, M Kremer, Oxford, England, 1965.
104. MCCANN VJ, DAVIS RE: Pyridoxine and diabetic neuropathy and a double blind controlled study. Diabetes Care 6: 102, 1983.
105. TSIGOS C, GIBSON S, CROSBY SR, ET AL: Cerebrospinal fluid levels of beta endorphin in painful and painless diabetic polyneuropathy. J Diabetes Complications 9: 92, 1995.
106. LEVIN ER, HANSCOM TA, FISHER M, ET AL: The influence of pyridoxine in diabetic peripheral neuropathy. Diabetes Care 4: 606, 1987.
107. COHEN KL, GORECK GA, SILVERSTEIN SB, ET AL: Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy. JAPA 74: 394, 1984.
108. HORIUCHI A, KOGURE K, TANAKA N, ET AL: "Relation of Partial Deficiency of Cobalamins to Occurrence of Diabetic Neuropathy," in Diabetic Neuropathy, ed by G Amsterdam, Y Goto, A Horiuchi, et al, Excerpta Medica, Amsterdam, 1982.
109. BECKETT AG, MATTHEWS DM: Vitamin B12 in diabetes mellitus. Clin Sci 23: 301, 1962.
110. SANCETTA SM, AYRES PR, SCOTT RW: The use of vitamin B12 in the management of the neurological manifestations of diabetes mellitus with notes on the administration of massive doses. Ann Intern Med 35: 1028, 1951.
111. HORIUCHI A, KOGURE K, YAMADA K, ET AL: "Treatment of Diabetic Peripheral Neuropathy with Methylcobalamin," in Diabetic Neuropathy, ed by G Amsterdam, Y Goto, A Horiuchi, et al, Excerpta Medica, Amsterdam 1982.
112. DUBNER R, BENNETT GJ: Spinal and trigeminal mechanisms of nociception. Ann Rev Neurosci 6: 381, 1983.
113. YOUNG RJ, EWING DJ, CLARKE BF: A controlled trial of sorbinil, an aldose reductase inhibitor in chronic painful diabetic neuropathy. Diabetes 32: 938, 1983.
114. MORRA M, PHILIPSZOON HD, D'ANDREA G, ET AL: Sensory and motor neuropathy caused by excessive ingestion of vitamin B6: a case report. Funct Neurol 8: 429, 1993.
115. FAGIUS J, BRATTBERG A, JAMESON S, ET AL: Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-week controlled trial. Diabetologia 28: 323, 1985.
116. HANDELSMAN DJ, TURTLE JR: Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30: 459, 1981.
117. RASKIN P, ROSENSTOCK J, CHALLIS P, ET AL: Effect of tolrestat on red blood cell sorbitol levels in patients with diabetes. Clin Pharmacol Ther 38: 625, 1985.
118. WIEMAN JT, PATEL VG: Treatment of hyperesthetic neuropathic pain in diabetes: decompression of the tarsal tunnel. Ann Surgery 221: 660, 1995.
119. EYAS-SMITH MG, MAX MB, MUIR J, ET AL: Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage enriched enrollment design. Pain 60: 267, 1995.
120. DELLON AL, MACKINNON SE, SEILER WA, IV: Susceptibility of the diabetic nerve to chronic compression. Ann Plast Surg 20: 117, 1988.
121. DELLON AL: Treatment of symptomatic diabetic neuropathy by surgical decompression of multiple peripheral nerves. Plast Reconstr Surg 89: 689, 1991.
122. FOSTER AVM, EATON DO, MCCONVILLE, ET AL: Application of OpSite film: a new and effective treatment of painful diabetic neuropathy. Diabet Med 11: 768, 1994.
123. WEBER GA, CARDILE MA: Diabetic neuropathies. Clin Podiatr Med Surg 7: 1, 1990.